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Abstract
Despite innovations in surgical interventions, treatment of cartilage injury in osteoar-
thritic joints remains a challenge due to concomitant inflammation. Obstructing a sin-
gle dominant inflammatory cytokine has shown remarkable clinical benefits in
rheumatoid arthritis, and similar strategies are being suggested to target inflamma-
tory pathways in osteoarthritis (OA). Here, we describe the utility of gelatin micro-
spheres that are responsive to proteolytic enzymes typically expressed in arthritic
flares, resulting in on-demand and spatiotemporally controlled release of anti-
inflammatory cytokines for cartilage preservation and repair. These microspheres
were designed with a net negative charge to sequester cationic anti-inflammatory
cytokines, and the magnitude of the negative charge potential increased with an
increase in crosslinking density. Collagenase-mediated degradation of the micro-
spheres was dependent on the concentration of the enzyme. Release of anti-
inflammatory cytokines from the loaded microspheres directly correlated with the
degradation of the gelatin matrix. Exposure of the IL-4 and IL-13 loaded micro-
spheres reduced the inflammation of chondrocytes up to 80%. Hence, the delivery of
these microspheres in an OA joint can attenuate the stimulation of chondrocytes and
the resulting secretion of catabolic factors such as proteinases and nitric oxide. The
microsphere format also allows for minimally invasive delivery and is less susceptible
to mechanically induced drug release. Consequently, bioresponsive microspheres can
be an effective tool for cartilage preservation and arthritis treatment.
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1 | INTRODUCTION
Osteoarthritis (OA) is the primary cause of disability among adults
worldwide (Neogi, 2013). OA is a degenerative joint disease that
affects one or more diarthrodial joints and is commonly associated
with inflammation and tissue breakdown. OA is a whole-joint disease
that includes changes in articular cartilage, subchondral bone, liga-
ments, and synovium and subsequent joint failure (Martel-Pelletier
et al., 2016). OA starts with the “wear and tear” of the cartilage
caused primarily due to trauma, obesity, and aging. Although the etiol-
ogy of OA is still elusive (Boehme & Rolauffs, 2018), chondrocyte-
mediated inflammatory events driven by the stimulation of innate
immune receptors by damage-associated molecules are thought to be
the primary cause. The damage-associated molecules activate the
synovial macrophages (type A) and fibroblasts (FBs) (type B), causing
synovitis. The activated synovial cells release catabolic and pro-
inflammatory factors that lead to a positive-feedback loop of synovial
cell activation, inflammation, and cartilage catabolism (Nefla,
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Holzinger, Berenbaum, & Jacques, 2016). When a significant amount
of cartilage matrix is degraded, typical symptoms of OA are exhibited,
including joint pain, tenderness, stiffness, loss of flexibility, grating
sensation, and bone spurs.
Several therapeutic agents, including chondroprotective drugs and
growth factors, anti-inflammatory cytokines, extracellular matrix constit-
uents, and immunomodulatory stem cells, have been tested to attenuate
the cartilage damage (Ying, Tyler, & Ming, 2014). However, the disease-
modifying interventions that specifically suppress inflammation are
thought to be most efficacious for the prevention and treatment of carti-
lage destruction (Joshi et al., 2018; Sokolove & Lepus, 2013). Among the
many inflammatory cytokines, tumor necrosis factor-alpha (TNF-α) sig-
naling and interleukin 1 beta (IL-1β) are the major mediators of cartilage
destruction (Malemud, 2004). Although a low level of these factors may
be required for normal homeostasis, inflammatory and oxidative condi-
tions disrupt the balance and drive the pathogenesis of OA. Inhibitors of
secretion/activity of TNF-α and IL-1β including receptor agonists and
monoclonal antibodies are capable of mitigating cartilage breakdown
(Kawaguchi et al., 2009; Martel-Pelletier, Mineau, Jolicoeur, Cloutier, &
Pelletier, 1998; Scott & Kingsley, 2006). More importantly, the applica-
tion of anti-inflammatory cytokines including IL-4, IL-10, and IL-13 are
capable of reducing inflammation while stimulating protective chondro-
cyte metabolic response (Lubberts et al., 1999; Lubberts, Joosten,
Helsen, & van den Berg, 1998; Ying et al., 2014). Studies have confirmed
the inhibitory effects of anti-inflammatory cytokines on matrix
metalloproteinases secretion, proteoglycans degradation, and chondro-
cyte apoptosis (Behrendt et al., 2016, 2018; Wojdasiewicz,
Poniatowski, & Szukiewicz, 2014). Together, the anti-inflammatory cyto-
kines are capable of exhibiting both anti-catabolic and anabolic effects
for cartilage maintenance. Therefore, these anti-inflammatory cytokines
have been proposed as therapeutic agents to modulate the inflammatory
response and help prevent chondrocytes hypertrophy and subsequent
osteophyte formation (Wojdasiewicz et al., 2014).
Other therapeutic agents include cartilage anabolic factors such
as transforming growth factor-beta (TGFβ), FB growth factors, and
insulin-like growth factor-I that are capable of partially recovering
chondrocytes function (Andia & Maffulli, 2013; Ying et al., 2014). Sim-
ilarly, chondroprotective drugs and matrix constituents such as glucos-
amine sulfate, chondroitin sulfate, hyaluronic acid, and diacerein are
shown to decrease NF-kB activation mediated by IL-1β (Gouze et al.,
2002). A key limitation of the anabolic factors and chondroprotective
matrices is that they may mitigate the cartilage breakdown but cannot
prevent the infiltration of immune cells. Nevertheless, their effects
can be synergistically enhanced when co-delivered with anti-
inflammatory cytokines (Ying et al., 2014). Alternatively, nonsteroidal
anti-inflammatory drugs (NSAIDs) that reduce inflammation by
inhibiting the cyclooxygenase enzymes (COX 1 & 2) are commonly
prescribed to relieve the joint pain (Jiang et al., 2010; Noble, King, &
Olutade, 2000). However, long-term usage of NSAIDs leads to gastro-
intestinal complications and cardiovascular disease.
Together, delivering anti-inflammatory cytokines to the OA joints
has the potential to suppress inflammation while stimulating or
augmenting chondroprotective mechanisms. They are safe, allow
quick cartilage recovery, and can be effective at almost all stages of
the arthritis progression. However, they possess short articular half-
lives, which reduce their therapeutic efficacy. For example, IL-10 has
a half-life of 2–3 hr at body temperature (Suga, Keshavjee, & Liu,
2005). Therefore, an efficient drug delivery vehicle is essential to
improve the drug residence time and hence enhance the therapeutic
efficacy of anti-inflammatory cytokines.
Polymeric biomaterials are generally attractive for controlled
release of macromolecular substances such as peptides and large
proteins owing to their chemical tunability (Fenton, Olafson, Pillai,
Mitchell, & Langer, 2018). Several materials have been tested for
articular drug delivery including chitosan (Zhou et al., 2015),
poly(lactic-co-glycolic) acid, nanosilicates (Cross, Carrow, Ding,
Singh, & Gaharwar, 2019), Poly(N-isopropylacrylamide) (McMasters,
Poh, Lin, & Panitch, 2017), and avidin (Bajpayee, Quadir, Ham-
mond, & Grodzinsky, 2016). However, clinical translation has, so far
is minimal. Here, we describe a microsphere drug delivery system
that is responsive to OA flares, resulting in on-demand and spatio-
temporally controlled release of cytokines for immunomodulation
and subsequent cartilage preservation (Figure 1). The microspheres
studied were made out of gelatin crosslinked by genipin, which
allows ionic complexation and sequestration of charged anti-
inflammatory cytokines. Gelatin polypeptides were chosen due to
their easy tunability (Gómez-Guillén, Giménez, López-Caballero, &
Montero, 2011) and lower immunogenicity compared to their pre-
cursor collagen due to the removal of aromatic groups (Lynn,
Yannas, & Bonfield, 2004; Rose et al., 2014). Furthermore, genipin is
more biocompatible than chemical crosslinkers (Tsai, Huang, Sung, &
Liang, 2000) and the degree of crosslinking can be controlled
through the concentration and incubation time (Solorio, Dhami,
Dang, Vieregge, & Alsberg, 2012; Solorio, Zwolinski, Lund, Farrell, &
Stegemann, 2010). The microspheres are injectable and exhibit deg-
radation and drug release controlled by the proteolytic enzymes
characteristically expressed by the inflamed chondrocytes and mac-
rophages in OA. These drug delivery vehicles can titrate the drug
release to synchronize with the inflammatory response while reduc-
ing the washout of drugs during periods of low disease activity.
Based on the endogenous mechanisms, the anti-inflammatory cyto-
kines IL-4, IL-10, and IL-13 were chosen for this study. The charge
potential of the microspheres to sequester the cationic cytokines
was investigated. The degradation of the microspheres and the
release kinetics of the cytokines were characterized using enzymatic
treatment. We show that controlling the crosslinking density and
hence the charge potential allows regulating both the cytokine load-
ing and releasing capacity of the microspheres. Finally, we show that
inflammatory cell-mediated release of cytokines from gelatin micro-
spheres can alleviate the inflammation of IL-1β and lipopolysaccha-
ride (LPS)-activated chondrocytes. Such biomaterial-based
approaches can be used to synchronize drug release during inflam-
mation, and thereby prolong the therapeutic effects and the resi-
dence time of anti-inflammatory cytokines.
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2 | MATERIALS AND METHODS
2.1 | Microsphere fabrication
Gelatin microspheres were made by emulsification of solubilized gela-
tin and subsequent crosslinking using genipin. Briefly, gelatin from
porcine skin (type A, 175 bloom, Sigma) was dissolved in calcium and
magnesium-free phosphate-buffered saline (1× PBS; Invitrogen, Carls-
bad, CA) to make a 6 wt % stock solution. The 1–2 ml of stock solu-
tion was then dispensed dropwise to polydimethylsiloxane (PDMS)
bath kept at 40C. The mixture was stirred for 5 min using a dual
radial-blade impeller at 2,000 rpm to emulsify the gelatin solution in
PDMS. After the emulsification process, the emulsion was cooled in
an ice bath and mixed for an additional 25 min to promote gelation.
Then 1 wt % genipin (Wako Chemicals) in PBS was added to the emul-
sion (2 ml genipin solution per 90 ml emulsion) and mixed at
1,500 rpm for an additional 30 min in the ice bath to initiate
crosslinking. The mixture was then collected in 50 ml centrifuge tubes
and mixed with 0.1 vol/vol % of non-ionic surfactant solution and vig-
orously mixed to encourage phase separation and centrifugation at
200g for 5 min. After centrifugation, the PDMS supernatant was
decanted without disturbing the pelleted microsphere. The micro-
spheres were washed three times with the surfactant solution. The
influence of surfactants on emulsification was also tested by adding
0.1 vol/vol % of non-ionic surfactant solution during the emulsifica-
tion of gelatin in PDMS solution. Two surfactants Pluronic® L101
(denoted as L101, BASF, Milford, CT) and Tween® 20 (denoted as
Tween, Sigma) with different hydrophilic–lipophilic balance (HLB)
were tested. L101 has an HLB in the range of 1–7, due to a large
hydrophobic end, whereas Tween has an HLB around 17 due to its
large hydrophilic chain (Kim & Hsieh, 2001). These structural differ-
ences not only influence their properties as an emulsifier but also
determine their cytotoxicity (Annamalai, Naik, Prout, Putnam, &
Stegemann, 2018). The microspheres made from 1 ml of gelatin
hydrogel were then suspended in 5 ml of 1 wt % genipin in PBS to
promote complete crosslinking. The mixture was incubated at room
temperature, and samples were collected at 3, 6, 12, and 24 hr and
washed with 100% ethanol to remove genipin. The microspheres
were then washed three times with deionized water to remove left-
over salts and stored in −80C. Then, the frozen microspheres were
lyophilized to remove residual water and stored at −20C for further
characterization.
2.2 | Cell culture
A mouse chondrogenic cell line (ATDC-5, derived from teratocarci-
noma AT805, Sigma) and a primary human lung FB cell line (Lonza,
Walkersville, MD) obtained from commercial sources were used to
characterize gelatin microspheres. ATDC-5 is a commonly used
chondrogenic cell line, which is shown to emulate the articular carti-
lage phenotype (Mayhew et al., 2014). Hence, ATDC-5 was deemed
suitable for characterizing the bioresponsive therapeutic delivery sys-
tem in this study. On the other hand, FBs are commonly rec-
ommended for cytotoxicity analysis of medical devices (Isama,
Matsuoka, Haishima, & Tsuchiya, 2002). They are robust for vector-
mediated transduction of fluorescent proteins allowing for easy cell
tracking (Annamalai, Rioja, Putnam, & Stegemann, 2016). Further-
more, synovial FBs are vital players in arthritic flares (Huber et al.,
2006) and are active in the synovium—the intended delivery site of
the microspheres. Hence, a FB cell line was deemed suitable for the
cytotoxicity analysis of microspheres. For morphological analysis and
temporal visualization of cell proliferation using fluorescent micros-
copy, the FB was transduced with a lentiviral vector expressing green
fluorescent protein (GFP) as described previously (Annamalai et al.,
2016). Stably transfected cells were selected using puromycin
F IGURE 1 Bioresponsive microspheres for delivery of the anti-inflammatory cytokines in osteoarthritis (OA). (a) The crosslinking of gelatin
using amine-reactive genipin imparts a net negative charge on microspheres, which is used to sequester cationic cytokines electrostatically.
(b) The microcarriers allow for minimally invasive delivery and are less susceptible to mechanically induced drug release and are conformant to the
intra-articular space. (c) The microspheres exhibit degradation and drug release controlled by the proteolytic enzymes characteristically expressed
by the inflamed chondrocytes and macrophages in OA. These drug delivery vehicles can titrate the drug release to synchronize with the
inflammatory response while reducing the washout of drugs during periods of low disease activity
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treatment. Finally, highly fluorescent FB was sorted out using cell
sorter (MoFlo Astrios EQ, Beckman Coulter) and used for experi-
ments. The chondrogenic cells were cultured in Dulbecco's modified
eagle medium (DMEM)/F12-Glutamax culture media (ThermoFisher,
Waltham, MA) supplemented with 5% fetal bovine serum (FBS, Ther-
moFisher) and 1% penicillin–streptomycin (ThermoFisher). The FBs
were cultured in DMEM (ThermoFisher) supplemented with 10% FBS
and 1% penicillin–streptomycin. The cell response to degradation and
cytokine release from the microspheres were characterized by meta-
bolic performance, cell proliferation, and inflammation assays. The cell
response was characterized in both 2D (tissue culture-treated surface)
and 3D pellet cultures (chondrocytes only).
2.3 | Cell proliferation and viability assay
The cell proliferation was assessed through the quantification of
double-stranded DNA using Quant-iT™ Picogreen™ dsDNA assay kit
(Invitrogen), and the metabolic performance was quantified using
PrestoBlue™ Reagent (Invitrogen). Briefly, cells were seeded at a cell
density of 5,000 cells/cm2 in a 24-well plate, and after 48 hr of incu-
bation, microspheres were added. To avoid aggregation, 5 mg of
microsphere was suspended in 1 ml of PBS and sonicated on ice for
2 min at 10% amplitude using a probe sonifier (Branson, Danbury,
CT). Then, 100 μg of microspheres were added to each well on top of
the cells and cell proliferation and metabolic activity were quantified
at days 0, 1, 3, and 7 using corresponding assays. The values were
then compared with untreated controls.
2.4 | Inflammatory cytokine treatment and
quantification of inflammation
The capability of drug-loaded microspheres to resurrect chondrocytes
under osteoarthritic conditions was tested as follows. Microspheres
loaded with recombinant murine interleukin 4 (IL-4, Peprotech, Rocky
Hill, NJ) with a molecular weight of 13.5 kDa, recombinant murine
interleukin 10 (IL-10, Peprotech) with a molecular weight of 18.7 kDa,
and recombinant murine interleukin 13 (IL-13, Peprotech) with a
molecular weight of 12.3 kDa, along with corresponding positive and
negative control conditions were tested. First, the chondrocytes were
seeded at a cell density of 50,000 cells/cm2 in a 24-well plate and
stimulated with inflammatory cytokines and endotoxin to mimic the
inflammatory environment of OA. Several inflammatory cytokines and
endotoxin were tested, including recombinant murine IL-1β
(Peprotech), LPS (Sigma), interferon-gamma (IFNγ, Peprotech), and
TNF-α (Peprotech) to induce an inflammatory chondrocyte pheno-
type. Then, the inflammatory state of chondrocytes was quantified by
measuring the nitric oxide (NO) production using Griess Reagent kit
(Invitrogen), as described previously (Hayashi, Abe, Yamate, Taguchi, &
Jasin, 1997). Briefly, 75 μl of culture supernatant was mixed with
75 μl of Griess reagent (1% sulfanilamide in 5% phosphoric acid and
1% N-(1-naphthyl) ethylenediamine dihydrochloride), incubated for
5 min at 37C, and the optical density was measured at 540 nm using
a plate reader (Synergy H1™, Biotek, Winooski, VT).
2.5 | Microspheres characterization
The physical and biochemical properties of the microspheres were
thoroughly characterized using confocal imaging and analysis, zeta
potential analysis, enzymatic degradation analysis, cytokine loading
and release studies, and cell culture studies. The crosslinking of gelatin
using amine-reactive genipin imparted a net negative charge on
microspheres and a unique fluorescence response at 590/620 Ex/Em
wavelengths. The distinct fluorescence was used for the physical and
morphological characterization of the microspheres. Confocal stacks
of the microspheres were taken using Nikon A1 confocal microsphere
for morphological analysis and quantification of size variability. The
confocal stacks were processed using Image J software (National
Institute of Health) to measure the diameter of the microspheres. A
violin plot was created to show the size distribution and variability of
the microspheres among different conditions.
The zeta potential of the microspheres was measured using a
Zetasizer (Malvern, Westborough, MA). The zeta potential of the
microspheres is the assessment of the charge affinity that can be used
to drive the polyionic complexation with the cationic cytokines,
including IL-4, IL-10, and IL-13. The microspheres were suspended in
a neutral sucrose solution (13 wt %) as per the manufacturer's recom-
mendations to avoid aggregation and settling of the microspheres.
The microspheres were sonicated for 2 min at 10% amplitude in ice
using probe sonifier before each measurement.
For cytokine loading, the lyophilized microspheres were swelled
in PBS and suspended in concentrated cytokine stock solution (20–
40 μg/ml) overnight at 37C. For loading 1 mg of dry microspheres,
10–20 μl of the cytokine stock solution was supplied and incubated
under static conditions. The loading concentrations were determined
empirically. Loaded microspheres were then washed in PBS containing
10 mg/ml albumin to remove unbound cytokines. The loading effi-
ciency was determined by measuring the concentrations of cytokines
in the wash buffer using the respective cytokine ELISA kit (R&D Sys-
tems). The supplier's recommended stock concentrations of 40, 40,
and 20 μg/ml, for IL-4, IL-10, and IL-13, respectively, showed maxi-
mum loading based on the release rates. However, no detectable
unbound peptides were seen in the loading solution even at higher
loading concentration. This is presumably due to the very low half-
lives of unbound cytokines in aqueous solution at 37C. Hence, the
loading was reported based on the total protein released after degra-
dation instead of the unbound protein detected in the loading solu-
tion, which can be misleading.
For enzymatic degradation and release studies, 100 μg of micro-
spheres were sonicated, loaded with cytokines, and suspended in col-
lagenase solution (Worthington, CLSPA: Activity 1,090 Units/mg) and
kept at 37C until complete degradation. The degradation of
the crosslinked microspheres was measured fluorometrically by mea-
suring the fluorescence of the supernatant every 5 min for 48 hr at
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590/620 Ex/Em. The fluorescence of the crosslinked microspheres
also allowed the visualization of their morphology. The cytokines
released from the degrading microspheres were measured by ELISA
(R&D Systems).
For cell-mediated degradation and release studies, microspheres
loaded with recombinant murine IL-4, IL-10, IL-13, and corresponding
positive and negative control conditions were tested. First, the cho-
ndrocytes were seeded at a cell density of 50,000 cells/cm2 in a
24-well plate and stimulated with inflammatory cytokines (IL-1β,
Peprotech; IFNγ, Peprotech; TNF-α, Peprotech) and endotoxin (LPS, a
toll-like receptor 4 [TLR4] activator, Sigma) to mimic the inflammatory
environment of OA. After 24 hr, 1 μg of cytokine-loaded and control
microspheres were added to each well of the 24-well plate. Culture
media samples were collected at specific time points. The inflamma-
tory state of chondrocytes was quantified by measuring the NO pro-
duction in the culture media samples using the Griess Reagent kit, as
described in Section 2.4.
2.6 | Statistical analysis
All measurements were performed at least in triplicate. Data are pres-
ented as mean ± 1 SD. Analysis of variance (ANOVA) was used for
multigroup comparisons, and Student's t test with a 95% confidence
limit (two-tailed and unequal variance) was used for paired comparisons,
and the p-values adjusted with Bonferroni correction wherever applica-
ble. Differences with p < .05 were considered statistically significant.
3 | RESULTS AND DISCUSSION
3.1 | Microsphere fabrication and influence of
surfactant treatment
The bioresponsive microspheres were fabricated by water-in-oil emul-
sification of a gelatin solution, which produced spherical droplets on
the same size scale as mammalian cells (10–30 μm). As the sol–gel
transition of gelatin is around 30C, it is imperative to crosslink the
matrix to enhance stability under physiological conditions. Genipin, a
relatively nontoxic natural crosslinking agent compared to other
chemical crosslinkers (Tsai et al., 2000), was employed to stabilize the
gelatin matrix, which yielded insoluble microspheres. The size of the
microspheres can be modified through various factors, including the
speed of emulsification and the viscosity of gelatin and PDMS solu-
tions. The application of surfactants was investigated to attain a
homogenous size distribution of microspheres, which enables a more
predictable degradation and drug release rates. Tween and L101 are
nonionic surfactants commonly used in biotechnology and pharma-
ceutical applications (Gates, Grad, Birek, & Lee, 1994; Tomlinson,
Demeule, Lin, & Yadav, 2015). The amphiphilic surfactant molecules
localize to the water–oil interface, which is thermodynamically
favored (Lawrence & Rees, 2000). A one-way ANOVA of the size dis-
tribution showed that the addition of the surfactants (0.1% L101 or
0.1% Tween) during emulsification yielded microspheres with signifi-
cantly smaller diameters compared to the non-surfactant PBS control
(p < .01, Table 1). The surfactant treatment also reduced the size vari-
ability, providing a more homogenous population of microspheres
compared to PBS control (Figure 2).
This effect is due to the stabilization of the droplets by the surfac-
tant molecules that prevent droplet growth (coalescence) (Rowe,
1965). In addition, smaller droplets can be formed more easily in the
surfactant-treated conditions because of lower dynamic interfacial
tensions. The size of the microspheres is also crucial in determining
the loading capacity of the vehicles because the internal loading vol-
ume is proportional to the square of the radius. Although smaller
microspheres can limit the drug loading capacity, they can minimize
mechanically induced drug release and facilitate smoother articular
movements of the knee. The degree of crosslinking of the gelatin
matrix, varied by the incubation period in the genipin crosslinking
solution, had no significant effect on the microsphere size and its dis-
tribution (Figure 2). Overall, the surfactant treatment not only reduced
the mean size of the microspheres but also narrowed the size distribu-
tion of microspheres compared to that of PBS control condition.
3.2 | Cytotoxicity of surfactant-treated
microspheres
The cytotoxicity of the microspheres fabricated through surfactant
treatment and genipin crosslinking was investigated through the
quantification of cell metabolism and proliferation. Human FBs were
chosen as a test cell type and were co-cultured with microspheres
fabricated with different treatments. No change in cell metabolism
was noticed when the cells were co-cultured with microspheres
(Figure 3a). However, the rate of cell proliferation quantified through
a DNA assay showed slightly altered growth rates in surfactant-
TABLE 1 The influence of surfactant treatments on microspheres size distribution
Hours of
crosslinking



















6 27.9 ± 7.7 27.1 14.2 ± 3.8 14.6 13.9 ± 4.3 13.2 p < .001 p < .001 p = .092
12 27.7 ± 7.7 27.5 16.6 ± 4.1 16.2 15.3 ± 4.4 15.5 p < .001 p < .001 p = .080
24 35.4 ± 11.1 36.2 17.3 ± 4.2 16.8 16.0 ± 3.9 15.6 p < .001 p < .001 p = .018
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treated conditions. The L101 treatment, although it did not exhibit
any short-term cytotoxicity, affected the cell proliferation in the
long-term cultures, as evident by a ~20% reduction in cell prolifera-
tion on day 7 compared to the control (Figure 3b). On the other
hand, Tween treatment showed short-term cytotoxicity as seen
from the reduced cell proliferation rate at 24 hr, but the cells recov-
ered within 7 days of culture (Figure 3b). The fluorescent micro-
graphs of the GFP-FBs taken at various time points showed no
differences in cell morphology and proliferation among the different
conditions (Figure 3c). The differences in the cytotoxicity of the sur-
factants are likely due to the differences in HLB of the surfactants
and their subsequent ability to penetrate the cell membrane.
Although the effects are minor, Tween was chosen as the standard
surfactant for microsphere fabrication due to its improved ability to
maintain cell viability over the long term. For further characteriza-
tion and microsphere use, multiple washes were incorporated for
the thorough removal of any residual surfactants in the
microspheres.
3.3 | Influence of crosslinking density on the
charge potential of microspheres
The crosslinking density of the microspheres can be controlled by
varying the genipin incubation period (Annamalai et al., 2018; Solorio
et al., 2010). The genipin crosslinking reaction occurs in two steps:
First, the primary amines in gelatin form an intermediate through
Michael addition, followed by a secondary amide link formation with
the genipin ester group through nucleophilic substitution (Annamalai,
Turner, et al., 2018). The influence of the crosslinking density on the
charge potential of the microspheres was characterized by measuring
zeta potential. Based on the cytotoxicity analyses discussed above,
Tween was used as the standard surfactant for microsphere fabrica-
tion (Figure 4a, confocal images of microspheres fabricated with
Tween). The increase in crosslinking density correlated with a
decrease in surface charge of the microspheres as measured through
the zeta potential (Figure 4b). A slight but not significant reduction in
zeta potential was seen between the microspheres that were
crosslinked with genipin for 6 and 12 hr. However, microspheres
crosslinked for 24 hr showed a drastic decrease in the zeta potential
(p < .05). The charge potential of the microsphere is a crucial driving
force in ionically complexing the cationic cytokines, including IL-4
(pI = 9.17), IL-10 (pI = 8.19), and IL-13 (pI = 8.69) to the gelatin matrix.
The control over the crosslinking density and hence, the charge
potential helps to optimize the cytokines loading and releasing capac-
ity of the microspheres.
3.4 | Enzymatic degradation and cytokine release
from microspheres
The bioresponsivity of the microspheres is the result of their selective
degradability to the enzymes characteristically expressed in
OA. During inflammation, many contributing cells secrete matrix-
degrading catabolic enzymes at levels not usually seen under physio-
logical conditions. These catabolic enzymes can degrade the
crosslinked-gelatin matrix in a concentration-dependent manner. The
resulting bioresponsivity can be optimized through the method and
the extent of crosslinking. In this study, the microspheres were
treated with genipin to ensure a crosslinking density of ~90% of the
primary amines such that the degradation happens only during the
onset of an inflammatory flare.
To demonstrate the bioresponsivity of the microspheres, the
microspheres were subjected to enzymatic degradation at increas-
ing collagenase concentrations. Treatment of gelatin microspheres
with different concentrations of collagenase at 37C exhibited a
dose-dependent degradation rate (Figure 5a). The degradation rate
was insignificant under control conditions (complete culture media,
0 U/ml of collagenase), while at high collagenase concentrations
(>5 U/ml), there was a rapid degradation of the microspheres. At
F IGURE 2 The influence of
surfactant treatments on microspheres
size distribution. The addition of nonionic
surfactants Tween and L101 (0.1%)
during gelatin emulsification yielded
homogenous microspheres with a
narrower size distribution compared to
control PBS condition. The degree of
crosslinking of the gelatin matrix, varied
by the incubation period in the genipin
crosslinking solution, had no significant
effect on the microsphere size and its
distribution. The solid line within the plot
indicates the median and the dotted lines
on the lower and upper ends represent
the 25th and 75th quartile, respectively.
n.s. indicates no statistical significance
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5 U/ml collagenase treatment, a steady rate of degradation of
microspheres was seen that lasted for more than 48 hr. Hence,
5 U/ml collagenase treatment was used to characterize the cytokine
release from the microspheres. The anti-inflammatory cytokines
were loaded into the crosslinked microspheres through electrostatic
sequestration by the negatively charged microspheres. The micro-
spheres were loaded with 200–400 ng of IL-4, IL-10, or IL-13 per
mg of the microspheres. Upon collagenase degradation, the
F IGURE 3 Cytotoxicity of the microspheres. (a) Human fibroblasts (FB) co-cultured with microspheres fabricated with different treatments
exhibited no change in cell metabolism. (b) However, the rate of cell proliferation (DNA assay) showed slightly altered growth rates in
microspheres produced with surfactants. The L101 treatment, although it did not exhibit any short-term cytotoxicity, showed a ~20% reduction
in cell proliferation on day 7 compared to the control. Tween treatment, on the other hand, showed short-term cytotoxicity, but the cells
recovered within 7 days of culture. (c) The fluorescent micrographs of the GFP-fibroblasts taken at various time points demonstrated no
differences in cell morphology and proliferation among the different conditions. Scale bars indicate 150 μm in length. n.s. indicates no statistical
significance and * indicates p < .05
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cytokines were released from the microspheres at rates that linearly
correlated with the rate of degradation of the microspheres
(Figure 5b).
We were able to achieve a maximum loading and subsequent
release of 40 ng/mg of IL-4 (Figure 6a), 120 ng/mg of IL-10
(Figure 6b), and 100 ng/mg of IL-13 (Figure 6c). In all formulations, the
F IGURE 4 Charge potential
of the microspheres. (a) Confocal
images of microspheres
fabricated with Tween treatment
showing spherical morphology.
(b) The zeta potential
measurements of the
microspheres showed a
correlation between the increase
in crosslinking density of the
gelatin matrix and a decrease in
surface charge potential. *
indicates p < .05
F IGURE 5 Enzymatic degradation of microspheres and release of cytokines. (a) Collagenase treatment of gelatin microspheres at 37C
exhibited a dose-dependent degradation. The degradation rate was insignificant in culture media (0 U/ml of collagenase), while rapid degradation
of the microspheres was seen at high collagenase concentrations (>5 U/ml). (b) Upon collagenase degradation, the cytokines IL-4, IL-10, and IL-13
were released from the respective microspheres at rates that linearly correlated with the rate of degradation
F IGURE 6 Enzymatic degradation and release of cytokines. A maximum loading and subsequent release of (a) 40 ng/mg of IL-4, (b) 120 ng/
mg of IL-10, and (c) 100 ng/mg of IL-13 were achieved using the microspheres. In all conditions, the release rate of the cytokines linearly
correlated with the rate of microsphere degradation (R2 ≥ 0.87, p < .05)
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release rate of the cytokines linearly correlated with the rate of micro-
sphere degradation (Figure 5, R2 ≥ 0.87, p < .05). These results demon-
strate the on-demand delivery of cytokines from the microspheres in a
catabolic microenvironment.
3.5 | Chondrocyte stimulated with inflammatory
agents create an osteoarthritic phenotype
During OA, the anabolic pathways of chondrocytes including collagen
type II and aggrecan production are turned off while
metalloproteinases and NO production are upregulated (Rahmati,
Mobasheri, & Mozafari, 2016). Such an osteoarthritic chondrocyte
phenotype would be the ideal culture model to validate the efficacy
of drug-loaded microspheres. To create such a phenotype, inflamma-
tory mediators that are commonly implicated in chondrocyte activa-
tion were studied. Specifically, LPS (a TLR4 activator), IL-1β, IFNγ, and
TNF-α were tested. The resulting osteoarthritic chondrocyte pheno-
type was evaluated and compared through the quantification of NO,
the key mediator in the progression of OA (Studer, Jaffurs,
Stefanovic-Racic, Robbins, & Evans, 1999). Murine IL-1β (2 ng/ml),
LPS (200 ng/ml), IFNγ (10 ng/ml), or TNF-α (10 ng/ml) were individu-
ally supplemented in the growth media and supplied to the mouse
chondrogenic cells (ATDC-5). The cells were then cultured for 48 hr,
and cellular NO production was measured at various time points using
the Griess assay (Figure 7). The assay indicated that TNF-α and IFNγ
treatment did not induce any increase in the NO concentration of the
cells. However, IL-1β and LPS showed a significant increase in NO
production within 12 hr. The chondrocyte activation by IL-1β is mainly
induced by the activation of nuclear factor κB, which is ubiquitously
expressed transcription factor that mediates inflammatory and cata-
bolic event in OA (Marcu et al., 2010). TLR4, on the other hand, is a
type of pattern-recognition receptor that binds not only LPS but also
host-derived debris known as damage-associated damage patterns
generated during catabolic events (Gómez, Villalvilla, Largo, Gualillo, &
Herrero-Beaumont, 2014). Therefore, IL-1β and LPS can faithfully rep-
licate the chondrocyte phenotype exhibited in OA. Hence, they were
chosen for the activation of chondrocytes and subsequent testing of
drug-loaded microspheres.
3.6 | Microspheres modulated the inflammatory
phenotype of activated chondrocytes
Chondrocytes were stimulated with murine IL-1β (2 ng/ml) or LPS
(200 ng/ml) to create an OA phenotype that was validated by their
upregulated NO production (Figure 7). The activated chondrocytes
were then treated with IL-4, IL-10, or IL-13 loaded microspheres
(maximum load 40, 120, and 100 ng of respective cytokine/mg of
microspheres) and the NO production was quantified at day 3. The
NO production by the microspheres treated cultures was compared
to that of the corresponding bolus treatment cultures in which
200 mg of respective cytokines were directly supplemented in the
F IGURE 7 Chondrocyte activation using anti-inflammatory
agents. Chondrocytes subjected to TNF-α and IFNγ treatment did not
show any increase in the NO production. However, IL-1β and LPS
stimulated chondrocytes showed a significant increase in NO
production within 12 hr compared to control and other treatment
conditions. Therefore, IL-1β and LPS treatment were chosen to
reproduce the OA chondrocyte phenotype. * indicates p < .05
F IGURE 8 Modulation of inflammation by cytokine-loaded
microspheres. NO production by the chondrocytes treated with
(a) bolus supplementation of 200 mg of cytokines in the culture media
and (b) microsphere treatment condition were quantified and
compared. The results showed that the IL-4 and IL-13 released from
the microspheres successfully reduced the chondrocyte inflammation
by 65–80% within 3 days while IL-10 showed only a marginal effect
with no significant decrease in NO production compared to untreated
controls. Compared to bolus treatment, the microspheres mediated
delivery of the anti-inflammatory cytokines exhibited comparable or
better performance. * indicates p < 0.05
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growth media and replenished every 24 hr (Figure 8a). The NO pro-
duction of the chondrocytes showed that the IL-4 and IL-13 released
from the microspheres successfully reduced the chondrocyte inflam-
mation by 65–80% within 3 days (Figure 8b, Table 2) while IL-10
showed only a marginal effect with no significant decrease in NO pro-
duction compared to untreated controls. IL-10, although a potent
anti-inflammatory cytokine, is known to primarily elicit anti-
inflammatory activity only in synergy with other anti-inflammatory
cytokines (van Roon, Lafeber, & Bijlsma, 2001). Hence, only a marginal
suppression of inflammation is seen in IL-10 treated conditions.
Compared to bolus treatment, microsphere-mediated delivery of
the anti-inflammatory cytokines exhibited a comparable or better per-
formance (Table 2). It should be noted that 2–5 times more cytokines
were added to the bolus treatments compared to the microsphere
treatment and were replenished every 24 hr to account for the short
half-lives of the cytokines. These results show that the microspheres
are efficient in titrating the drug release depending on the inflamma-
tory response while reducing drug washout. Furthermore, the micro-
spheres are biodegradable and can be quickly removed from the
synovium once digested by the catabolic factors. Their breakdown
products are nontoxic and did not show any agonistic influence on
inflammatory pathways. This is noteworthy because the extended res-
idence of nondigestible substances is known to cause inflammation
and contribute to OA. Furthermore, the microcarrier format allows for
minimally invasive delivery, is less susceptible to mechanically induced
drug release, and is conformant to the intra-articular space. Taken
together, bioresponsive microspheres can be an effective tool for car-
tilage preservation and arthritis treatment. Moreover, localized deliv-
ery of therapeutics can avoid undesirable systemic effects commonly
seen with the use of other anti-inflammatory substances such as
cyclooxygenase-2 inhibitors (Zarghi & Arfaei, 2011).
4 | CONCLUSIONS
We have created bioresponsive gelatin microspheres that can prolong
the half-life of anti-inflammatory cytokines while reducing their wash-
out during periods of low disease activity. The gelatin microspheres
are made through a facile emulsification procedure followed by
appropriate post-processing that allowed tailoring the crosslinking
density and the charge potential of the matrix. The negative charge
potential of the microspheres allowed ionic complexation and seques-
tration of cationic anti-inflammatory cytokines. We previously
showed that the genipin crosslinking density could be optimized such
that the microspheres can be preferentially degraded by inflammatory
cells and not by other noninflammatory cells (Annamalai, Turner, et al.,
2018). Applying the same principle, the microspheres were made pref-
erentially degradable by the catabolic factors symptomatically
secreted by the inflamed chondrocytes and macrophages in OA. We
have shown that the therapeutics sequestered in the microspheres
stay intact for a prolonged period hence extending their half-lives.
The therapeutics maintain their potency upon release and fully exhibit
biological function. The enzymatic degradation of the microspheres
was concentration-dependent, and the release of the cytokines line-
arly correlated with the degradation rates. The IL-4 and IL-13 loaded
microspheres co-cultured with osteoarthritic chondrocytes reduced
their inflammation by up to 80%. Such on-demand delivery systems
that are synchronized with the catabolic responses may find general
utility in wound healing, particularly in preventing inflammation-
mediated cartilage damage in OA.
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